Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference Synteract to present on risk-benefit analysis of technology platforms to expedite clinical development
SAN DIEGO and PHILADELPHIA, March 19, 2012 /PRNewswire/ -- Toby Odenheim, director of IT services at Synteract, Inc., a full-service contract research organization (CRO), is slated to present on Selecting the Optimum EDC Platform to Support your Clinical Program at the Outsourcing in Clinical Trials, East Coast conference, to be held in Philadelphia, March 27-28, 2012. Odenheim will speak at 11 a.m. EDT, Wed., March 28, discussing a variety of drivers to consider when selecting the right EDC (electronic data capture) platform for clinical project needs.
The conference is geared towards solution-seeking professionals who want focused research-generated content and innovative strategies to manage the increased complexities in today's drug development environment. Odenheim will discuss working with clients to identify the key drivers for consideration when evaluating electronic data capture platforms to match program needs, such as:
- Developing a checklist and risk-benefit evaluation to assist in decision-making
- Assessing different platforms during a clinical program to enhance productivity, cost efficiency and expedite decision points
- Scrutinizing EDC systems for biotech and pharma development needs
Odenheim has been with Synteract for seven years. He has a master's in business administration and a bachelor's degree in biology, as well as a professional Oracle Database Administration certificate from the University of California San Diego.
According to Stewart Bieler, chief operating officer, Odenheim was chosen to present on behalf of Synteract due to his clear understanding of how critical the application of appropriate technologies is in driving efficiencies and productivity in drug development.
"This is a complex industry that is changing all the time, and clients want to be assured their project will be in the right hands, with a company that has experience helping clients choose the right tools and technology for their drug development needs. Toby has assessed and helped to deliver solutions to clients that best fit their unique program requirements, driving projects and results forward at the same time."
Synteract will exhibit in booth #35; Synteract CEO, Wendel Barr, will also be on hand at the event. Synteract will answer questions about the multiple software and technology platforms it supports within the framework of its full-service CRO capabilities and will discuss how its more than 17 years of experience across a wide range of therapeutic areas can fit specific project needs. To set up an appointment in advance, contact Michele Sacher, associate business development director, at 484.467.5937 or at email@example.com
About Synteract (www.synteract.com)
Synteract is a full-service contract research organization with a successful 17-year track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its "Shared Work – Shared Vision" philosophy Synteract provides customized Phase I through IV services collaboratively and cost effectively to ensure on-time delivery of quality data so clients get to decision points faster. Headquartered in California, with offices in North Carolina and the Czech Republic, Synteract delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, cardiovascular, respiratory and ophthalmology.
Clearpoint Agency, for Synteract
SOURCE Synteract, Inc.